
Biagio Ricciuti, MD, discusses how access challenges and toxicity concerns slow the rollout of new T-cell engager therapies from academic centers into community oncology.

Biagio Ricciuti, MD, is a medical thoracic oncologist at the Dana-Farber Cancer Institute.

Biagio Ricciuti, MD, discusses how access challenges and toxicity concerns slow the rollout of new T-cell engager therapies from academic centers into community oncology.